
## **Supplemental Figure S1.**


	MGLPTLEFSDSYLDSPDFRERLQCHEIELERTNKFIKELLKDGSLLIGALRNLSMAVQKF MGLPTLEFSDSYLDSPDFRERLQCHEIELERTNKFIKELTKDGSLLIGALRNLSMAVQKF >BAR domain	60 60
	SQSLQDFQFECIGDAETDDEISIAQSLKEFARLLIAVEEERRRLIQNANDVLIAPLEKFR SQSLQDFQFECIGDAETDDEISIAQSLKEFARLLIAVEEERRRLIQNANDVLIAPLEKFR	120 120
ARHGAP42_Mm ARHGAP42_Hs	KEQIGAAKDGKKKFDKESEKYYSILDKHLNLSAKKKESHLQEADSQIGREHQNFYEASLE KEQIGAAKDGKKKFDKESEKYYSILEKHLNLSAKKKESHLQEADTQIDREHQNFYEASLE	180 180
	YVFKIQEVQEKKKFEFVEPLLSFLQGLFTFYHEGYELAQEFAPYKQQLQFNLQNTRNNFE YVFKIQEVQEKKKFEFVEPLLSFLQGLFTFYHEGYELAQEFAPYKQQLQFNLQNTRNNFE	240 240
	STRQEVERLMQRMKSANQDYRPPSQWTMEGYLYVQEKRPLGFTWTKHYCTYDKGSKMFTM STRQEVERLMQRMKSANQDYRPPSQWTMEGYLYVQEKRPLGFTWTKHYCTYDKGSKTFTM BAR domain	300 300
	SVSD <u>VKA</u> SGKMNGLVTGSPEMFKLKSCIRRKTDSIDKRFCFDIEVVERHGIITLQAFSEA SVSE <u>MKS</u> SGKMNGLVTSSPEMFKLKSCIRRKTDSIDKRFCFDIEVVERHGIITLQAFSEA	360 360
	NRKLWLEAMDGKEPI <b>Y</b> TLPAIISKKEEMYLNEAGFNFVRKCIQAVE <u>M</u> RGITILGLYRIGG NRKLWLEAMDGKEPI <b>Y</b> TLPAIISKKEEMYLNEAGFNFVRKCIQAVE <u>T</u> RGITILGLYRIGG <u>PH domain</u> < >RhoGAP domain	420 420
	VNSKVQKLMNTTFSPKSPPDMDIDIELWDNKTITSGLKNYLRCLAEPLMTYKLHKDFIIA VNSKVQKLMNTTFSPKSPPDIDIDIELWDNKTITSGLKNYLRCLAEPLMTYKLHKDFIIA	480 480
	VKSDDQNYRVEAVHALVHKLPEKNREMLDILIKHLLKVSLHSQQNLMTISNLGVIFGPTL VKSDDQNYRVEAVHALVHKLPEKNREMLDILIKHLVKVSLHSQQNLMTVSNLGVIFGPTL	540 540
	MRAQEETVAAMMNIKFQNIVVEILIEHYEKIFHTAPDPNIPLPQPQSRSGSRRTRAICLS MRAQEETVAAMMNIKFQNIVVEILIEHYEKIFHTAPDPSIPLPQPQSRSGSRRTRAICLS RhoGAP domain<	600 600
	${\tt TGSRKPRGRYTPCLAEPDSDSYSSSPDSTPMGSIESLSSHSSEQNSTTKS} {\tt TACQPREKSGTGSRKPRGRYTPCLAEPDSDSYSSSPDSTPMGSIESLSSHSSEQNSTTKS {\tt ASCQPREKSGTGSRKPRGRYTPCLAEPDSDSYSSSPDSTPMGSIESLSSHSSEQNSTTKS {\tt ASCQPREKSGTGSRKPRGSTGSRKPGSTGSRKPRGSTGSRKPRGSTGSRKPRGSTGSRKPRGSTGSRKPRGSTGSRKPGSTGSRKPGTGSTGSRKPGSTGSRKPGSTGSRKTGSTGSRKPGGSTGSRKTGSTGSRKTGSTGSTGSRKTGSTGSRKTGSTGSRKTGSTGSRKTGSTGSRKTGST$	660 660
	GIPWITTPSSSNGQKSQGLWTTSPESSSREDATKTDVESDCQSVASITIPGNVSPPIDLV GIPWIATPSSSNGQKSLGLWTTSPESSSREDATKTDAESDCQSVASVTSPGDVSPPIDLV	720 720
	KKGPYGLSGLKRSSASSSLRSISAAEGNKSYSGSIQSLTSIGSKESPKAIPNPELPPKMC KKEPYGLSGLKRASASS-LRSISAAEGNKSYSGSIQSLTSVGSKETPKASPNPDLPPKMC	780 779
ARHGAP42_Mm ARHGAP42_Hs	RRLRLDTASSNGYQRPGSVVAAKAQLFENAGSPKPVSSGRQAQAMYSCKAEHSHELSFPQ RRLRLDTASSNGYQRPGSVVAAKAQLFENVGSPKPVSSGRQAKAMYSCKAEHSHELSFPQ >SH3 domain	840 839
	GAIFSNVHPSVEPGWLKATYEGRTGLVPENYVVFL* 875 GAIFSNVYPSVEPGWLKATYEGRTGLVPENYVVFL* 874  SH3 domain<	

**Supplemental Figure S1. Mouse vs. human ARHGAP42.** Mouse ARHGAP42 (ARHGAP42\_Mm) is shown aligned against the predicted human protein (ARHGAP42\_Hs; UniProt accession number A6NI28). Non-identical residues are shaded. Asterisks indicate STOP codons. Numbers indicate amino acid position. Positions of BAR, PH, GAP, and SH3 domains are shown below the aligned sequences. The Tyr-376 phosphorylation site is in bold and indicated by a box. Note that the UniProt entry for mouse RhoGAP42 (accession number B2RQE8, not shown) is missing amino acid residues 129-162 within the BAR domain.




Supplemental Figure S2. Subcellular localization of ARHGAP42 mutational variants. (A) GFP-ARHGAP42 variants DABAR, DABAR,

## **Supplemental Figure S3.**



Supplemental Figure S3. Expression of ARHGAP42- $\Delta$ GAP increases the size of focal adhesions. MEFs stably expressing GFP-ARHGAP42 variants (WT,  $\Delta$ BAR,  $\Delta$ GAP) were grown on fibronectin-coated cover slips, fixed and focal adhesion size was analyzed by fluorescence microscopy. The cells were immunostained with an antibody against paxillin to mark focal adhesions. (A) Representative images showing focal adhesions stained by paxillin; left: greyscale signal of paxillin, right: merge (blue: DAPI, green: GFP, red: Paxillin). Scale bars are 20  $\mu$ m. (B) Representative FRAP curves of mCherry-Vinculin dynamics in focal adhesions in MEFs expressing indicated variants of ARHGAP42. (C) Representative images of monolayer wound healing of MEFs expressing GFP-ARHGAP42 variants WT,  $\Delta$ BAR, and  $\Delta$ GAP.



Supplemental Figure S4. (A, B) Src phosphorylation of ARHGAP42 on Tyr376 regulates focal adhesion and lamellipodial dynamics. SYF cells or SYF cells expressing constitutively active Src (SrcF) were co-transfected with GFP-ARHGAP42 expression plasmids (WT, Y376F, and ΔBAR). Cells were plated on fibronectin covered glass bottom dishes and after 24 hours cells showing similar levels of GFP-ARHGAP42 fluorescence, judged using an integrated intensity value of the GFP signal per cell and acquired with same settings (exposure, laser power, detector gain, etc.) of the microscope, were analyzed by confocal live cell microscopy. (A) Representative color-coded images of cell expressing ARHGAP42 variants observed for 10 min. Color coding: 0 min – blue, 5 min – green, 10 min – red; dynamic adhesions are colored and stable adhesions are white. (B) Representative kymographs of protruding lamellipodia showing increased lamellipodium velocity in cells with increased ARHGAP42 activity. (C) Subcellular localization of endogenous ARHGAP42. MEFs were immunostained with ARHGAP42 antibody (green, endogenous ARHGAP42) and anti-Paxillin (red) antibody to mark focal adhesions. Scale bars is 30 μm. (D) Model showing ARHGAP42 activation by Src. The BAR and GAP domains are inhibitory towards one another. Upon Src phosphorylation of Tyr-376 the inhibition is disrupted. Activation of the GAP domain leads to a decrease of RhoA-GTP levels and subsequently to lowering of acto-myosin tension, increased focal adhesion dynamics and loss of stress fibers.